MedElevator Войти в исследования
← Поиск публикаций

DOI 10.25270/jic/21.00110

Медицинская библиотека · The Journal of invasive cardiology · 2022

Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients With Failing Bioprosthetic Aortic Valves: Mid-term Outcomes From the Italian CoreValve Clinical Service Project.

Mangieri Antonio, Khokhar Arif A, Petronio Anna Sonia, Giannini Cristina, Angelillis Marco, Fiorina Claudia, Adamo Marianna, Curello Salvatore, Tamburino Corrado, Barbanti Marco, Bedogni Francesco, Testa Luca, Iadanza Alessandro, Fineschi Massimo, Bruschi Giuseppe, Poli Arnaldo, Montorfano Matteo, Maffeo Diego, Colombo Antonio

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

We evaluated the acute and two-year safety and efficacy of using the Corevalve, Evolut R, and Evolut PRO valves for treating failed surgical bioprosthesis from the Italian CoreValve Clinical Service Project.

BACKGROUND

Valve-in-valve (ViV) TAVR is an emerging treatment option for failed surgical bioprosthesis. Choice of transcatheter valve is an important determinant of procedural and clinical outcomes, however, longer-term data are lacking.

METHODS

The Clinical Service Project is a national clinical data repository evaluating the use of implantable devices across Italy. The present multi-center analysis includes consecutive patients who underwent ViV-TAVR with the Medtronic CoreValve series between October 2008 to June 2019. Evaluated endpoints included rates of overall mortality, cardiovascular mortality, myocardial infarction, and cerebrovascular accidents at 2-year follow-up. Procedural success, complications, and echocardiographic outcomes were reported according to VARC-2 criteria.

RESULTS

A total of 139 patients (mean age, 80 ± 7 years; 47.5% male; mean STS score, 10.0 ± 9.7%) underwent ViV-TAVR with CoreValve (28.5%), Evolut R (68.6%), and Evolut Pro (2.9%) valves. Device success was achieved in 68% and acute coronary obstruction requiring PCI was observed in 4 patients (2.9%). Moderate PVL was observed in 3.7% and 2.8% of patients at 30-day and 2-year follow-up and moderate structural valve degeneration seen only 5 patients (3.6%). All-cause and cardiovascular mortality were 3.6% and 2.9% at 30 days, respectively, and 20.6% and 10.2% at 2-year follow-up.

CONCLUSIONS

This real-world nationwide analysis demonstrates the acute and longer-term safety and efficacy of using the self-expanding Medtronic THV for ViV-TAVR.

Для цитирования: Mangieri Antonio, Khokhar Arif A, Petronio Anna Sonia, Giannini Cristina, Angelillis Marco, Fiorina Claudia, Adamo Marianna, Curello Salvatore, Tamburino Corrado, Barbanti Marco, Bedogni Francesco, Testa Luca, Iadanza Alessandro, Fineschi Massimo, Bruschi Giuseppe, Poli Arnaldo, Montorfano Matteo, Maffeo Diego, Colombo Antonio. Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients With Failing Bioprosthetic Aortic Valves: Mid-term Outcomes From the Italian CoreValve Clinical Service Project.. The Journal of invasive cardiology. 2022. DOI: 10.25270/jic/21.00110.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.